Results 121 to 130 of about 164,514 (305)

Extralevator Abdominoperineal Excision Improves Overall Survival Compared to Standard Abdominoperineal Excision: A Systematic Review and Meta‐Analysis

Annals of Gastroenterological Surgery, EarlyView.
This systematic review and meta‐analysis of 38 studies, encompassing over 5000 patients, compared extralevator abdominoperineal excision (ELAPE) with standard abdominoperineal excision (APE) in patients with advanced low rectal cancer. ELAPE was associated with significantly improved overall and disease‐free survival, reduced intraoperative perforation
Sarolta Beáta Kávási, Diana‐Elena Floria, Anett Rancz, Dániel Sándor Veres, Nándor Faluhelyi, Pál Miheller, Péter Hegyi, Szabolcs Ábrahám   +7 more
wiley   +1 more source

Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim To examine the significance of portal vein tumor thrombus (PVTT) as a prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC) treated with chemoradiotherapy (CRT) followed by surgery. Methods The study retrospectively examined 313 patients with borderline resectable (BR) or locally advanced (LA) PDAC who underwent CRT ...
Aoi Hayasaki, Motonori Nagata, Miki Usui, Hiroshi Imai, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno   +9 more
wiley   +1 more source

Risk stratification for adjuvant radiotherapy in pathologic T3N0 rectal cancer using a DeepSurv-based survival model

Frontiers in Oncology
BackgroundThe role of adjuvant radiotherapy in patients with pathologic T3N0 rectal cancer remains controversial. Although overall prognosis is favorable, marked heterogeneity exists, and reliable tools to identify patients who may derive meaningful ...
Yunxia Huang, Yunxia Huang, Yanzong Lin, Qingyang Zhuang, Xinyuan Wu, Qiping Fan, Junxin Wu   +6 more
doaj   +1 more source

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa, Itaru Yasufuku, Hironori Ishigami, Masahiro Yura, Takanobu Yamada, Shigeaki Baba, Takeshi Kubota, Erina Nagai, Seito Fujibayashi, Mitsumasa Yoshida, Takahiro Kinoshita, Nobuhisa Matsuhashi, Masanori Terashima   +12 more
wiley   +1 more source

Does obesity hinder radiotherapy in endometrial cancer patients? The implementation of new techniques in adjuvant radiotherapy – focus on obese patients

, 2014
The increasing incidence of obesity in Poland and its relation to endometrioid endometrial cancer (EEC) is resulting in the increasing necessity of treating obese women.
Małgorzata Moszyńska-Zielińska, Justyna Chałubińska-Fendler, Leszek Gottwald, Leszek Żytko, Jacek Fijuth, Małgorzata Moszyńska-Zielińska, Ewelina Bigos   +6 more
core   +1 more source

Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12‐Year Retrospective Cohort Study of 3487 Consecutive Patients

Annals of Gastroenterological Surgery, EarlyView.
In this retrospective cohort of 3487 patients with CRC, history of CCY was associated with significantly worse prognosis in patients with proximal CRC but not in those with distal CRC. This differential prognostic impact showed a statistically significant interaction between tumor location and history of CCY and remained robust after PSM.
Masashi Tsunematsu, Koichiro Haruki, Kazuhiro Yanamoto, Takuo Takehana, Shunta Ishizaki, Mitsuru Yanagaki, Yoshihiro Shirai, Kenei Furukawa, Shinji Onda, Toru Ikegami   +9 more
wiley   +1 more source

The role of AIMP3, a putative tumour suppressor gene, as a predictive biomarker of response to chemo/radiotherapy in vitro and in patients with muscle-invasive bladder cancer.

, 2015
Bladder cancer is the second most common urological cancer after prostate cancer and is one of the leading causes of cancer mortality in most western countries.
Gurung, PMS
core  

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Neo-adjuvant radiotherapy in rectal cancer

World Journal of Gastroenterology, 2013
In rectal cancer treatment, attention has focused on the local primary tumour and the regional tumour cell deposits to diminish the risk of a loco-regional recurrence. Several large randomized trials have also shown that combinations of surgery, radiotherapy and chemotherapy have markedly reduced the risk of a loco-regional recurrence, but this has not
openaire   +2 more sources

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source